An observational study in Type 1 Diabetes, sponsored by DCB Research AG. Completed at 1 site in Switzerland. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by DCB Research AG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland — 9 open to participants now, 10 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Switzerland.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, this one is the 10th largest by enrollment of the 18 observational ones that give a count, is the only one that started in 2024, is one of 18 observational ones, and was the 70th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →9 of the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Switzerland, Canada
Ages 18+
DCB Research AG · Sites in Switzerland
Ages 18–40 · Women only
Sanofi · Sites in Switzerland, United States, Argentina and 17 more countries
Ages 1–25
University of Bern · Sites in Switzerland
Ages 18–65
Pediatric Clinical Research Platform · Sites in Switzerland
Ages 0–25 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 16
First in 1997; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is below the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 29 across the 52 interventional studies, 73 across the 18 observational. Of the 55 that completed or were terminated, 6 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 70 have an industry lead sponsor. The 10 most frequent:
DCB Research AG is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
DCB Research AG has 3 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetes Mellitus, Type 1 with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05594706University Hospital, GenevaAnhydroglucitol in Children With Type 1 Diabetes | 2026-12-31 |
| NCT05791201Vertex Pharmaceuticals IncorporatedA Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | 2027-03-12 |
| NCT06282055DCB Research AGTrajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes | 2027-09-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Automated insulin delivery (AID) systems substantially improve diabetes management in people with type 1 diabetes but do not account for menstrual cycle related changes in insulin sensitivity. As a result, many menstruating individuals rely on manual adjustments, such as entering fake carbohydrates, modifying insulin settings, or changing basal rates, to maintain glycemic control. This study aims to systematically characterize these manual adjustment strategies, estimate how frequently they are used across the menstrual cycle, and explore their perceived burden, effectiveness, and implications for the development of future AID algorithms that better address menstrual cycle related insulin variability.
Background Automated insulin delivery (AID) systems are expected to substantially improve diabetes management in people with type 1 diabetes but do not account for menstrual cycle related changes in insulin sensitivity, leading many menstruating individuals to rely on manual adjustments such as modifying insulin settings or entering "fake carbohydrates" to maintain glycemic control. This study will address the limited evidence in this area by systematically characterizing the range of manual adjustment strategies used across the menstrual cycle to inform the development of future AID systems.
Methods A mixed methods study design will be used, comprising an online survey followed by semi structured online focus groups with a subset of survey participants. The survey will capture self reported manual adjustment practices, while the focus groups will explore these strategies in greater depth through participant discussions to better understand the range, rationale, and variation of approaches used across the menstrual cycle.
Objectives The primary objective will be to identify and characterize manual adjustment strategies used by menstruating individuals with type 1 diabetes to compensate for menstrual cycle related changes in insulin requirements while using automated insulin delivery systems. Secondary objectives will include assessing the frequency, perceived burden and effectiveness of these strategies, their variation across the menstrual cycle, and identifying user needs to inform the development of future AID systems.
Outcomes Primary endpoints will be user reported manual adjustment strategies and perceptions of AID system use across the menstrual cycle. Secondary endpoints will include the frequency and perceived effectiveness of these strategies, user needs and preferences for AID systems, satisfaction with current system responsiveness, and the impact of menstrual cycle related adjustments on daily life.
Procedures Participants will be recruited through social media and partner networks and will complete an online REDCap survey that includes eligibility screening, informed consent, and collection of baseline characteristics, diabetes management, and menstrual cycle information. Eligible and interested participants will be invited to semi structured online focus groups (approximately five participants per group) to discuss manual adjustment strategies used during the menstrual cycle.
Statistical analysis No formal sample size calculation will be performed for the quantitative survey. Focus group data will be collected until thematic saturation is reached and will be analysed using thematic content analysis in Atlas.ti, involving transcription, coding, development of themes, and exploration of recurring patterns and relationships in manual adjustment strategies. Quantitative data will be analysed using R and Python.
Women with type 1 diabetes and menstrual cycle using AID system
Inclusion Criteria:
Type of manual adjustment to AID settings to manage menstrual cycle related changes in insulin requirement
Semi-structured interviews will be analyzed using reflexive thematic analysis. Participant-reported strategies used to adjust AID system behavior in response to menstrual cycle-related changes in insulin requirements will be coded into themes (e.g., fictitious carbohydrate entries, temporary glucose targets, manual boluses, profile changes). The number of participants reporting each strategy will be summarized descriptively.
Time frame: One full menstrual cycle (24 - 35 days)
Frequency of manual adjustments across the menstrual cycle
Identify frequencies of manual adjustments applied by the participants
Time frame: One full menstrual cycle (24 - 35 days)
Perceived burden related to manual adjustments (scale 1 - 5)
Perception of burden related to manual adjustments which are related to the menstrual cycle
Time frame: One full menstrual cycle (24 - 35 days)
Self-reported assessment of effectiveness of manual adjustment strategies on glucose control
Participants' self reported perception of how well manual adjustment strategies help maintain glycemic control and support diabetes management during different phases of the menstrual cycle.
Time frame: One full menstrual cycle (24 - 35 days)
Plan to share: Undecided — All data extracted from the recordings can be found in the manuscript on the study.
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Feb 2025, 4 months.
Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's 4 months is below that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
DCB Research AG